Market Place
Sourcing Support
Vera Therapeutics Appoints Christopher Hite To Board of Directors
05 Mar 2026 //
GLOBENEWSWIRE
Vera Updates Business And Reports 2025 Financial Result
26 Feb 2026 //
GLOBENEWSWIRE
Vera Therapeutics To Participate At Upcoming Investor Conferences
24 Feb 2026 //
GLOBENEWSWIRE
Vera Therapeutics Names Matt Skelton as Chief Commercial Officer
28 Jan 2026 //
GLOBENEWSWIRE
Vera Therapeutics Joins 44th J.P. Morgan Healthcare Conference
08 Jan 2026 //
GLOBENEWSWIRE
Vera Pharma`s Atacicept For IgA Nephropathy Gets FDA Priority
07 Jan 2026 //
GLOBENEWSWIRE
Vera Therapeutics Plans Public Offering Of Class A Common Stock
08 Dec 2025 //
GLOBENEWSWIRE
Vera Therapeutics Appoints James R. Meyers To Board
26 Nov 2025 //
GLOBENEWSWIRE
Company Redefines IgA Nephropathy Approach Targeting BAFF & APRIL
17 Nov 2025 //
FIERCE PHARMA
Vera Therapeutics Joins TD Cowen Immunology & Inflammation Summit
10 Nov 2025 //
GLOBENEWSWIRE
Vera Submits BLA To FDA For Atacicept In IgA Nephropathy
07 Nov 2025 //
GLOBENEWSWIRE
Vera Builds Strong Profile For Atacicept In IgAN Ahead Of Filing
07 Nov 2025 //
BIOSPACE
Vera Reports Positive ORIGIN Ph3 Results for Atacicept in IgAN
06 Nov 2025 //
GLOBENEWSWIRE
Vera Therapeutics Updates Business & Reports Q3 2025 Financials
05 Nov 2025 //
GLOBENEWSWIRE
Vera Therapeutics Hosts Investor Call For ORIGIN 3 Update On Nov
22 Oct 2025 //
GLOBENEWSWIRE
Vera Therapeutics To Present ORIGIN 3 Abstract At ASN Kidney
17 Oct 2025 //
GLOBENEWSWIRE
Vera Therapeutics to Participate at Upcoming Investor Conferences
26 Aug 2025 //
GLOBENEWSWIRE
Vera Therapeutics Updates Business and Reports Q2 2025 Financials
05 Aug 2025 //
GLOBENEWSWIRE
Otsuka`s Kidney Disease Trial Results Heat up Battle with Vera
07 Jun 2025 //
BUSINESSWIRE
Vera Therapeutics at Goldman Sachs 46th Annual Healthcare Conf.
04 Jun 2025 //
GLOBENEWSWIRE
Vera Therapeutics refinances Oxford debt, secures $500M term loan
03 Jun 2025 //
GLOBENEWSWIRE
Vera’s Atacicept Cut Proteinuria 46% in IgAN Nephropathy Phase 3
02 Jun 2025 //
GLOBENEWSWIRE
Vera Therapeutics Updates Business and Reports Q1 2025 Financials
06 May 2025 //
GLOBENEWSWIRE
Vera Acquires Global Rights To Dual BAFF/APRIL Inhibitor
13 Jan 2025 //
GLOBENEWSWIRE
Vera Therapeutics to Participate in 43rd J.P. Morgan Conference
07 Jan 2025 //
GLOBENEWSWIRE
Vera Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
09 Dec 2024 //
GLOBENEWSWIRE
Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer
18 Nov 2024 //
GLOBENEWSWIRE
Vera Therapeutics Partners with Michigan on Neptune Match & Pioneer
11 Nov 2024 //
GLOBENEWSWIRE
Vera Therapeutics to Participate at Upcoming Investor Conferences
08 Nov 2024 //
GLOBENEWSWIRE
Vera Therapeutics Q3 2024 Financial Results & Business Update
07 Nov 2024 //
GLOBENEWSWIRE
Vera Therapeutics Prices Public Offering of Class A Stock
29 Oct 2024 //
GLOBENEWSWIRE
Vera Therapeutics Proposes Class A Common Stock Offering
28 Oct 2024 //
#N/A
Vera Therapeutics Shows 96-Week eGFR Stabilization in IgAN
26 Oct 2024 //
GLOBENEWSWIRE
Vera Reports Inducement Grants Under Nasdaq LR 5635(c)(4)
04 Oct 2024 //
GLOBENEWSWIRE
Vera Therapeutics Presents ORIGIN Ph 2b Results at ASN Kidney Week
02 Oct 2024 //
GLOBENEWSWIRE
Vera Therapeutics To Host R&D Day On Atacicept Expansion
16 Sep 2024 //
GLOBENEWSWIRE
Vera Therapeutics Completes ORIGIN 3 Trial Enrollment For Atacicept
12 Sep 2024 //
GLOBENEWSWIRE
Vera Therapeutics to Participate at September Investor Conferences
29 Aug 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
09 Aug 2024 //
GLOBENEWSWIRE
Vera Therapeutics Reports Q2 2024 Results And Provides Business Update
08 Aug 2024 //
GLOBENEWSWIRE
Vera’ atacicept for treatment of IgAN receivesUS FDA breakthrough therapy desig.
30 May 2024 //
PHARMABIZ
Vera Atacicept IgAN Phase 2b: 72-Week Egfr Hematuria Data At Era Congress
25 May 2024 //
GLOBENEWSWIRE
Vera to Host Presentation of Week 36 Data from Ph2b ORIGIN Trial of Atacicept
15 Jun 2023 //
GLOBENEWSWIRE
Vera Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept
30 Jan 2023 //
GLOBENEWSWIRE
